Loading...
XNAS
SLS
Market cap183mUSD
Dec 05, Last price  
1.74USD
1D
0.00%
1Q
-8.90%
Jan 2017
-99.94%
IPO
-99.99%
Name

Sellas Life Sciences Group Inc

Chart & Performance

D1W1MN
XNAS:SLS chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
199.05%
Rev. gr., 5y
0.00%
Revenues
0k
0000002,038,0002,487,0009,319,000000001,900,0007,600,0001,000,00000
Net income
-31m
L-17.30%
-2,405,000-10,990,000-14,373,000-18,387,000-11,993,000-11,485,000-34,969,000-76,678,000-36,606,000-63,902,000-23,549,000-23,754,000-27,670,000-19,292,000-16,757,000-20,699,000-40,652,000-37,340,000-30,881,000
CFO
-35m
L+12.71%
-2,112,000-6,047,000-9,429,000-11,769,000-10,257,000-14,668,000-20,963,000-28,908,000-42,869,000-48,160,000-44,915,000-10,989,000-30,422,000-17,643,000-10,417,000-26,021,000-23,809,000-31,410,000-35,402,000
Dividend
Dec 09, 20100 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
URL
https://www.sellaslifesciences.com/
IPO date
Mar 12, 2008
Employees
17
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT